Patritumab Deruxtecan is a medication being studied for its potential to treat certain types of cancer. It is designed to target and attach to a specific protein found on the surface of some cancer cells. Once attached, it delivers a powerful anti-cancer agent directly into the cancer cell, which may help to stop the cancer from growing and spreading. This medication is being tested to see if it is safe and effective for children with solid tumors that have come back after treatment or have not responded to other treatments.

Hepatoblastoma – Hepatoblastoma is a rare malignant liver tumor that primarily affects children, usually under the age of three. It originates from immature liver precursor cells and can grow rapidly. The disease often presents as an abdominal mass, and symptoms may include abdominal pain, swelling, and weight loss. As the tumor progresses, it can invade nearby structures and spread to other parts of the body, such as the lungs. The growth of the tumor can lead to liver dysfunction and other systemic effects. Early detection is crucial for managing the disease effectively.

Rhabdomyosarcoma – Rhabdomyosarcoma is a rare type of cancer that forms in soft tissue, such as muscles, and is most common in children. It arises from cells that normally develop into skeletal muscles. The disease can occur in various parts of the body, including the head, neck, bladder, and extremities. Symptoms depend on the tumor’s location and may include a noticeable lump, pain, or functional impairment of the affected area. As the tumor grows, it can invade surrounding tissues and metastasize to distant sites, such as the lungs or bone marrow. The progression of rhabdomyosarcoma can lead to significant physical and systemic challenges.